Caution: If you are pregnant or nursing, consult your health care professional before taking this product
DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
We collected details on study characteristics (first author, publication year, trial name, sample size, study duration, and geographic region), population characteristics (mean age, sex distribution, and baseline BMI), intervention details (drug name, dose, dosing schedule, and duration), comparator treatments, and all prespecified outcomes
The Bottom Line HCG sits in a category most peptide catalogs get wrong
The difference is simple but profound
